search
Back to results

Preventing Adverse Incisional Outcomes at Cesarean Multicenter Trial (Prevena-C)

Primary Purpose

Surgical Wound Infection, Cesarean Section

Status
Terminated
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Prophylactic NPWT
Standard Dressing
Sponsored by
Indiana University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Surgical Wound Infection

Eligibility Criteria

16 Years - undefined (Child, Adult, Older Adult)FemaleAccepts Healthy Volunteers

Inclusion Criteria

  • Gestational age ≥23weeks
  • BMI≥30 Pre-pregnancy or BMI at first prenatal visit
  • Planned or unplanned cesarean delivery

Exclusion Criteria:

  • Non-availability for postoperative follow-up
  • Contraindication to NPWT applicable to women undergoing cesarean: Pre-existing infection around incision site, Bleeding disorder, Therapeutic anticoagulation, Irradiated skin, Allergy to any component of the dressing (e.g. silver, acrylic, silicone, adhesive tape)

Sites / Locations

  • University of Alabama Medical Center
  • Eskenazi Hopsital
  • Methodist Hospital
  • Ochsner Baptist Medical Center
  • Barnes-Jewish Hospital
  • Mercy Hosptial St Louis

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Prophylactic NPWT

Standard Dressing

Arm Description

Women assigned to prophylactic NPWT will have the Prevena device applied and secured with fixation adhesion strips. The device will be monitored while the patient is in the hospital to confirm that it is functioning well. The device will be removed prior to discharge, typically on postoperative day 4, but longer for up to 7 days for patients who remain hospitalized.

Women assigned to standard care will receive routine postoperative wound dressing consisting of layers of gauze and adhesive tap. The dressing will be removed after 24 - 48 hours.

Outcomes

Primary Outcome Measures

Number of Participants With Superficial or Deep Surgical Site Infections (SSIs)
As defined according to the Center for Disease Control and Prevention's (CDC) National Healthcare Safety Network criteria.

Secondary Outcome Measures

Number of Participants With Superficial, Deep or Organ Space SSIs (Individual Types of SSIs)
As defined according to the CDC's National Healthcare Safety Network criteria.
Number of Participants With Organ Space SSIs (Endometritis, Intraabdominal Abscess)
As defined according to the CDC's National Healthcare Safety Network criteria.
Number of Participants With Wound Hematoma, Seroma, Separation (Other Wound Complications)
Frequency of wound hematoma, seroma, separation (other wound complications). Hematoma, seroma, separation (2cm or more).
Number of Participants With a Composite of Any Wound Complication Including SSI, Hematoma, Seroma, Separation (2cm or More).
Frequency of a composite of any wound complication including SSI, hematoma, seroma, separation (2cm or more). SSI, hematoma, seroma, separation (2cm or more).
Patient Pain Score
On a scale of 0 (least) - 10 (most).
Patient Pain Score
On a scale of 0 (least) - 10 (most).
Patient Satisfaction Score
On a scale of 0 (least) - 10 (most).
Patient Satisfaction Score
On a scale of 0 (least) - 10 (most).
Number of Participants With Physician Office Visit, Emergency Room Visit, Attendance at Wound Clinic, Use Antibiotics, Hospital Readmission for Wound Related Problems (Measures of Healthcare Resource Utilization)
Frequency of physician office visit, emergency room visit, attendance at wound clinic, use antibiotics, hospital readmission for wound related problems (measures of healthcare resource utilization).
Number of Participants With Skin Blistering, Erythema, Wound Bleeding (Measures of Adverse Skin Events)
Frequency of skin blistering, erythema, wound bleeding (measures of adverse skin events).

Full Information

First Posted
December 28, 2016
Last Updated
May 9, 2023
Sponsor
Indiana University
Collaborators
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), 3M
search

1. Study Identification

Unique Protocol Identification Number
NCT03009110
Brief Title
Preventing Adverse Incisional Outcomes at Cesarean Multicenter Trial
Acronym
Prevena-C
Official Title
Prophylactic Negative Pressure Wound Therapy in Obese Women at Cesarean: a Multicenter Randomized Trial
Study Type
Interventional

2. Study Status

Record Verification Date
May 2023
Overall Recruitment Status
Terminated
Why Stopped
DSMB recommendation following interim analysis
Study Start Date
February 8, 2017 (Actual)
Primary Completion Date
November 13, 2019 (Actual)
Study Completion Date
November 13, 2019 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Indiana University
Collaborators
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), 3M

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The Prophylactic Negative Pressure Wound Therapy in Obese Women at Cesarean Trial is a large pragmatic multi-center randomized clinical trial designed to evaluate the effectiveness, safety and cost-effectiveness of prophylactic negative pressure wound therapy (NPWT) - a closed, sealed system that applies negative pressure to the wound surface via a single-use, battery-powered, portable device - to decrease surgical site infections (SSIs) in obese women.
Detailed Description
Experimental evidence suggests that NPWT promotes wound healing by removing exudate, approximating the wound edges, and reducing bacterial contamination. Obesity (body mass index [BMI] ≥30kg/m2) increases the risk for both cesarean delivery and SSIs compared to non-obese women. The increased risk of SSIs is in part due to the increased thickness of the subcutaneous space, allowing collection of exudates and increasing tension on wound edges, promoting the growth of bacteria, and leading to wound infection and breakdown. Thus, prophylactic NPWT may be particularly effective in this patient population. During the 5-year project period, investigators from 4 collaborating perinatal centers in the United Stated (two university and two community) will randomize 2850 obese women undergoing cesarean delivery to receive either prophylactic negative pressure wound therapy with the Prevena device or standard wound dressing. Women will be followed up to 30 days postoperatively to ascertain study outcomes. The primary outcome for the trial is superficial or deep SSI after cesarean according to the CDC's National Healthcare Safety Network definitions. The investigators will also assess other wound complications, adverse events potentially attributable to NPWT and cost-effectiveness as measured by incremental cost per case of SSI prevented and per quality-adjusted life year (QALY).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Surgical Wound Infection, Cesarean Section

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
1624 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Prophylactic NPWT
Arm Type
Experimental
Arm Description
Women assigned to prophylactic NPWT will have the Prevena device applied and secured with fixation adhesion strips. The device will be monitored while the patient is in the hospital to confirm that it is functioning well. The device will be removed prior to discharge, typically on postoperative day 4, but longer for up to 7 days for patients who remain hospitalized.
Arm Title
Standard Dressing
Arm Type
Active Comparator
Arm Description
Women assigned to standard care will receive routine postoperative wound dressing consisting of layers of gauze and adhesive tap. The dressing will be removed after 24 - 48 hours.
Intervention Type
Device
Intervention Name(s)
Prophylactic NPWT
Other Intervention Name(s)
Prevena
Intervention Description
The Prevena NPWT system is a small, lightweight, portable suction device consisting of an electric motor-driven vacuum pump connected to a proprietary foam and adhesive dressing. It is supplied as a pump with a sterile dressing kit and two batteries. Different dressing sizes are available for transverse and vertical incisions ranging from 13 to 20 cm and more. The pump maintains negative pressure of -125 mmHg to the wound surface. The device is placed after skin closure.
Intervention Type
Device
Intervention Name(s)
Standard Dressing
Intervention Description
Standard wound dressing is routine postoperative wound dressing consisting of layers of gauze and adhesive tape.
Primary Outcome Measure Information:
Title
Number of Participants With Superficial or Deep Surgical Site Infections (SSIs)
Description
As defined according to the Center for Disease Control and Prevention's (CDC) National Healthcare Safety Network criteria.
Time Frame
30 days postoperatively
Secondary Outcome Measure Information:
Title
Number of Participants With Superficial, Deep or Organ Space SSIs (Individual Types of SSIs)
Description
As defined according to the CDC's National Healthcare Safety Network criteria.
Time Frame
30 days postoperatively
Title
Number of Participants With Organ Space SSIs (Endometritis, Intraabdominal Abscess)
Description
As defined according to the CDC's National Healthcare Safety Network criteria.
Time Frame
30 days postoperatively
Title
Number of Participants With Wound Hematoma, Seroma, Separation (Other Wound Complications)
Description
Frequency of wound hematoma, seroma, separation (other wound complications). Hematoma, seroma, separation (2cm or more).
Time Frame
30 days postoperatively
Title
Number of Participants With a Composite of Any Wound Complication Including SSI, Hematoma, Seroma, Separation (2cm or More).
Description
Frequency of a composite of any wound complication including SSI, hematoma, seroma, separation (2cm or more). SSI, hematoma, seroma, separation (2cm or more).
Time Frame
30 days postoperatively
Title
Patient Pain Score
Description
On a scale of 0 (least) - 10 (most).
Time Frame
At discharge, an average of 4 days postoperatively
Title
Patient Pain Score
Description
On a scale of 0 (least) - 10 (most).
Time Frame
At postoperative day 30
Title
Patient Satisfaction Score
Description
On a scale of 0 (least) - 10 (most).
Time Frame
At discharge, an average of 4 days postoperatively
Title
Patient Satisfaction Score
Description
On a scale of 0 (least) - 10 (most).
Time Frame
At postoperative day 30
Title
Number of Participants With Physician Office Visit, Emergency Room Visit, Attendance at Wound Clinic, Use Antibiotics, Hospital Readmission for Wound Related Problems (Measures of Healthcare Resource Utilization)
Description
Frequency of physician office visit, emergency room visit, attendance at wound clinic, use antibiotics, hospital readmission for wound related problems (measures of healthcare resource utilization).
Time Frame
30 days postoperatively
Title
Number of Participants With Skin Blistering, Erythema, Wound Bleeding (Measures of Adverse Skin Events)
Description
Frequency of skin blistering, erythema, wound bleeding (measures of adverse skin events).
Time Frame
30 days postoperatively
Other Pre-specified Outcome Measures:
Title
Types and Frequency of Different Bacteria Including Methicillin-resistant Staphylococcus Aureus
Description
Types and frequency of different bacteria including methicillin-resistant Staphylococcus aureus.
Time Frame
30 days postoperatively
Title
Incremental Cost Per SSI Prevented
Description
Based on economic analysis to be done along side trial. Results of the economic analysis will be published separately from the effectiveness and safety data.
Time Frame
30 days postoperatively
Title
Incremental Cost Per Quality-Adjusted Life-year
Description
Based on economic analysis to be done along side trial. Results of the economic analysis will be published separately from the effectiveness and safety data.
Time Frame
30 days postoperatively
Title
Risk Factors for Surgical Site Infections in Obese Women
Description
Based on combined cohort. Results of the risk factor analysis will be published separately from the effectiveness and safety data.
Time Frame
30 days postoperatively

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
16 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria Gestational age ≥23weeks BMI≥30 Pre-pregnancy or BMI at first prenatal visit Planned or unplanned cesarean delivery Exclusion Criteria: Non-availability for postoperative follow-up Contraindication to NPWT applicable to women undergoing cesarean: Pre-existing infection around incision site, Bleeding disorder, Therapeutic anticoagulation, Irradiated skin, Allergy to any component of the dressing (e.g. silver, acrylic, silicone, adhesive tape)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Methodius G Tuuli, MD, MPH
Organizational Affiliation
Indiana University School of Medicine
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Alabama Medical Center
City
Birmingham
State/Province
Alabama
ZIP/Postal Code
35233
Country
United States
Facility Name
Eskenazi Hopsital
City
Indianapolis
State/Province
Indiana
ZIP/Postal Code
46202
Country
United States
Facility Name
Methodist Hospital
City
Indianapolis
State/Province
Indiana
ZIP/Postal Code
46202
Country
United States
Facility Name
Ochsner Baptist Medical Center
City
New Orleans
State/Province
Louisiana
ZIP/Postal Code
70115
Country
United States
Facility Name
Barnes-Jewish Hospital
City
Saint Louis
State/Province
Missouri
ZIP/Postal Code
63108
Country
United States
Facility Name
Mercy Hosptial St Louis
City
Saint Louis
State/Province
Missouri
ZIP/Postal Code
63141
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
24056202
Citation
Mark KS, Alger L, Terplan M. Incisional negative pressure therapy to prevent wound complications following cesarean section in morbidly obese women: a pilot study. Surg Innov. 2014 Aug;21(4):345-9. doi: 10.1177/1553350613503736. Epub 2013 Sep 20.
Results Reference
background
PubMed Identifier
26126306
Citation
Swift SH, Zimmerman MB, Hardy-Fairbanks AJ. Effect of Single-Use Negative Pressure Wound Therapy on Postcesarean Infections and Wound Complications for High-Risk Patients. J Reprod Med. 2015 May-Jun;60(5-6):211-8.
Results Reference
background
Citation
Bullough, L, Wilkinson, D., Burns, S, Wan, L, Changing wound care protocols to reduce postoperative caesarean section infection and readmission, Wounds , 2014 (10), 1 : 72 - 76. 46
Results Reference
background
PubMed Identifier
27429285
Citation
Chaboyer W, Anderson V, Webster J, Sneddon A, Thalib L, Gillespie BM. Negative Pressure Wound Therapy on Surgical Site Infections in Women Undergoing Elective Caesarean Sections: A Pilot RCT. Healthcare (Basel). 2014 Sep 30;2(4):417-28. doi: 10.3390/healthcare2040417.
Results Reference
background
PubMed Identifier
32960242
Citation
Tuuli MG, Liu J, Tita ATN, Longo S, Trudell A, Carter EB, Shanks A, Woolfolk C, Caughey AB, Warren DK, Odibo AO, Colditz G, Macones GA, Harper L. Effect of Prophylactic Negative Pressure Wound Therapy vs Standard Wound Dressing on Surgical-Site Infection in Obese Women After Cesarean Delivery: A Randomized Clinical Trial. JAMA. 2020 Sep 22;324(12):1180-1189. doi: 10.1001/jama.2020.13361.
Results Reference
derived

Learn more about this trial

Preventing Adverse Incisional Outcomes at Cesarean Multicenter Trial

We'll reach out to this number within 24 hrs